Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel long-acting anti-infectives for the treatment and prevention of diseases in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop antiviral conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
IPO Year: 2015
Exchange: NASDAQ
Website: cidara.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/8/2024 | $33.00 | Buy | Guggenheim |
| 8/14/2024 | $24.00 | Neutral → Buy | H.C. Wainwright |
| 12/3/2021 | $6.00 | Buy | H.C. Wainwright |
| 9/22/2021 | $9.00 → $8.00 | Buy | Aegis Capital |
| 9/22/2021 | $6.25 | Buy → Strong Buy | WBB Securities |
| 9/22/2021 | Buy → Strong Buy | WBB Securities |
4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
8-K - Cidara Therapeutics, Inc. (0001610618) (Filer)
10-Q - Cidara Therapeutics, Inc. (0001610618) (Filer)
8-K - Cidara Therapeutics, Inc. (0001610618) (Filer)
8-K - Cidara Therapeutics, Inc. (0001610618) (Filer)
S-8 - Cidara Therapeutics, Inc. (0001610618) (Filer)
8-K - Cidara Therapeutics, Inc. (0001610618) (Filer)
10-Q - Cidara Therapeutics, Inc. (0001610618) (Filer)
EFFECT - Cidara Therapeutics, Inc. (0001610618) (Filer)
424B3 - Cidara Therapeutics, Inc. (0001610618) (Filer)
S-1 - Cidara Therapeutics, Inc. (0001610618) (Filer)
SC 13G/A - Cidara Therapeutics, Inc. (0001610618) (Subject)
SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)
SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)
SC 13D - Cidara Therapeutics, Inc. (0001610618) (Subject)
SC 13G/A - Cidara Therapeutics, Inc. (0001610618) (Subject)
SC 13G/A - Cidara Therapeutics, Inc. (0001610618) (Subject)
SC 13G/A - Cidara Therapeutics, Inc. (0001610618) (Subject)
SC 13G/A - Cidara Therapeutics, Inc. (0001610618) (Subject)
SC 13G/A - Cidara Therapeutics, Inc. (0001610618) (Subject)
SC 13G/A - Cidara Therapeutics, Inc. (0001610618) (Subject)
SAN DIEGO, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that it has entered into a securities purchase agreement with certain investors to raise up to approximately $105 million in gross proceeds. The private placement is being led by new investor, Venrock Healthcare Capital Partners, and includes significant participation by new and existing life sciences-focused investors, including RA Capital Management, TCGX, BVF Partners LP, Vivo C
SAN DIEGO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in the Evercore 7th Annual HealthCONx Conference. Details are as follows: Event: Evercore 7th Annual HealthCONx ConferenceDate: Tuesday, December 3, 2024Time: 7:55 AM ET Format: Fireside chat Webcast: https://wsw.com/webcast/evercore44/cdtx/2373273 A replay of the presentation will be available in
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the third quarter ended September 30, 2024, and provided an update on its corporate activities and product pipeline. "The recent initiation of our Phase 2b NAVIGATE clinical trial, which will evaluate the efficacy and safety of CD388 for the pre-exposure prophylaxis of seasonal influenza, represents an important clinical achievement for our compa
SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in the following November investor conferences. Details are as follows: Event: Guggenheim Securities Healthcare Innovation ConferenceDate: Monday, November 11, 2024Time: 1:30 PM ET Format: Fire side chat Webcast: https://wsw.com/webcast/guggen/cdtx/1949799 A replay of the presentation will be avai
SAN DIEGO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced two upcoming presentations at IDWeek 2024, to be held October 16–19, 2024 in Los Angeles, CA. The presentations will highlight clinical data on the safety, pharmacokinetics, and prophylactic activity of Cidara's clinical-stage influenza DFC asset, CD388. "We are pleased to share these clinical results at this year's IDWeek, which underscore the potential for CD388 as an effective
SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that the Compensation Committee of its Board of Directors (Compensation Committee) granted Dipesh Bhatt, a new employee, a non-qualified stock option award and restricted stock units (RSUs) for an aggregate of 1,110 shares of its common stock, pursuant to the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, as amended (the Inducement Plan), with a grant date of September
SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced two presentations at OPTIONS XII for the Control of Influenza conference, to be held September 29 through October 2, 2024 in Brisbane, Australia. The presentations, one oral and one poster, will highlight safety and pharmacokinetic (PK) data from clinical studies of CD388, Cidara's influenza drug-Fc conjugate (DFC) candidate. "We are pleased to have the opportunity to present at
SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the first subjects dosed in the Phase 2b NAVIGATE trial to evaluate the efficacy and safety of CD388 for the pre-exposure prophylaxis of influenza during the current flu season. The Phase 2b clinical trial is a randomized, double blind, controlled trial targeting 5,000 healthy unvaccinated adult subjects who are not at risk of complications from influenza. Three CD388 dose groups
SAN DIEGO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the appointment of Rick Bright, Ph.D., Philip Krause, M.D., Mario Barro, Ph.D., and Frederick G. Hayden, M.D., FACP to its Scientific Advisory Board (SAB). "We are honored that these four esteemed physicians and scientists have agreed to join our Scientific Advisory Board," said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. "They have already provided i
SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced a reduction in its workforce to focus on the clinical development of CD388, the Company's novel DFC candidate for influenza A and B. The planned reduction impacts approximately 30% of the Cidara workforce. These strategic initiatives are expected to substantially reduce capital needs and allow Cidara to focus on its planned Phase 2b and potential subsequent trials investigating C
- $240 million private placement financing led by RA Capital Management with significant participation by Bain Capital Life Sciences as well as BVF Partners and Canaan Partners to fund Phase 2b clinical trial - CD388, which is active against all strains of influenza A and B, is being developed for pre-exposure prophylactic treatment - Company to host business strategy update conference call and webcast today at 4:30 PM ET SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve
Submitted NDA for rezafungin for candidemia and invasive candidiasis to the U.S. FDA on July 22, 2022, with an anticipated PDUFA target action date in the first quarter of 2023, if accepted for review following application validationMelinta acquires exclusive rights to commercialize rezafungin in the U.S.Cidara to receive up to $460 million, with an upfront cash payment of $30 million, $60 million in regulatory milestones, and up to $370 million in commercial milestones, plus tiered low double digits to mid-teens royalties on net salesCidara to focus on advancing Cloudbreak DFC platform in oncology and viral infections SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc
Trial met FDA and EMA-pre-specified primary endpoints versus daily standard of care Data to support global regulatory filings in mid-2022 Cidara to host investor conference call today, December 14th, at 8:30 a.m. EST to provide further details on the data SAN DIEGO and CAMBRIDGE, United Kingdom, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) and Mundipharma today announced positive topline data from the pivotal ReSTORE Phase 3 clinical trial evaluating the efficacy and safety of its once-weekly antifungal candidate rezafungin as a potential first-line treatment for candidemia and invasive candidiasis. Rezafungin met the primary endpoint for the U.S. Food and
4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
4/A - Cidara Therapeutics, Inc. (0001610618) (Issuer)
4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
SAN DIEGO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the appointment of Rick Bright, Ph.D., Philip Krause, M.D., Mario Barro, Ph.D., and Frederick G. Hayden, M.D., FACP to its Scientific Advisory Board (SAB). "We are honored that these four esteemed physicians and scientists have agreed to join our Scientific Advisory Board," said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. "They have already provided i
SAN DIEGO, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Jim Beitel, MBA, has joined the company as its Chief Business Officer ("CBO"). Following recent transactions, Cidara is focused exclusively on advancing its Cloudbreak DFC pipeline, which provides numerous partnering and licensing opportunities, and a dedicated CBO will be a vital resource for the organization. Preetam Shah, Ph.D., MBA, who has held the roles of both Chief Fi
Dr. Davarpanah will lead Cidara's oncology efforts, focusing on strategy to advance development candidates Previously served as Clinical and Translational Lead in Oncology at Genentech/Roche SAN DIEGO, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the appointment of Nicole Davarpanah, M.D., J.D., as Senior Vice President of Translational Research & Development. In this position, Dr. Davarpanah will lead the company's oncology efforts
SAN DIEGO, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced the appointments of Preetam Shah, Ph.D., MBA, as chief financial officer and chief business officer, and Shane Ward as chief legal officer and corporate secretary. "We are excited to welcome Preetam and Shane to Cidara's executive team," said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. "They are joining us during an exciting time in the Company's history, as we prepare for top-line data from the pivotal
SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the three months and full year ended December 31, 2020 and provided an update on its corporate activities and product pipeline. “We are pleased with our progress across our rezafungin Phase 3 trials and Cloudbreak platforms despite the pandemic-related challenges imposed during the course of 2020. We continue to expect top-line data from the ongoing ReSTORE trial by the end of 2021,” said Jeffrey Stein, Ph.D.,
SAN DIEGO, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced the appointment of Christopher (Chris) Kurtz as executive vice president of technical operations. Mr. Kurtz brings more than 26 years of experience in global manufacturing, engineering, supply chain, CMC development and program management for drugs and devices at various stages of development. “We are pleased to welcome Chris to our leadership team at such a pivotal time for our antifungal and antiviral programs,” said Jeffrey Stei
Cantor Fitzgerald analyst Louise Chen reiterates Cidara Therapeutics (NASDAQ:CDTX) with a Overweight.
Needham analyst Joseph Stringer reiterates Cidara Therapeutics (NASDAQ:CDTX) with a Buy and maintains $25 price target.
Cidara Therapeutics (NASDAQ:CDTX) reported quarterly losses of $(2.28) per share which missed the analyst consensus estimate of $(0.20) by 1040 percent. The company reported quarterly sales of $8.46 million which beat the analyst consensus estimate of $6.30 million by 34.33 percent. This is a 67.44 percent decrease over sales of $25.99 million the same period last year.
WBB Securities analyst Stephen Brozak maintains Cidara Therapeutics (NASDAQ:CDTX) with a Strong Buy, adjusts target to $40 (reverse stock split - 1:20).
Needham analyst Joseph Stringer maintains Cidara Therapeutics (NASDAQ:CDTX) with a Buy, adjusts target to $25 from $3.
Shares of Caterpillar Inc. (NYSE:CAT) fell sharply during Thursday's session after the company reported better-than-expected first-quarter EPS but missed revenue estimates. Caterpillar reported a first-quarter fiscal 2024 revenue of $15.8 billion, a slight decrease of 0.4% year-over-year, missing the consensus of $16.216 billion. CAT's adjusted earnings of $5.60 per share, compared to $4.91 a year ago, topped the consensus of $5.14, according to data from Benzinga Pro. Caterpillar shares dipped 6.6% to $339.37 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers Barfresh Food Group, Inc. (NASDAQ:BRFH) surged 87.2% to $2.05. Safe & Green Holdin
Cantor Fitzgerald analyst Louise Chen reiterates Cidara Therapeutics (NASDAQ:CDTX) with a Overweight.
ULBI: 26% | Ultralife shares are trading higher after the company reported better-than-expected Q1 financial results.CDTX: 41% | Cidara Therapeutics shares are trading higher after the company announced the divestiture of rezafungin to Mundipharma, reacquired global development and commercial rights to CD388 and announced $240 million in private placement financing. OPTN: 36% | Optinose Provides Corporate Updates; Expects To Produce Positive Income From Operations For Full Year 2025
Guggenheim initiated coverage of Cidara Therapeutics with a rating of Buy and set a new price target of $33.00
H.C. Wainwright upgraded Cidara Therapeutics from Neutral to Buy and set a new price target of $24.00
H.C. Wainwright resumed coverage of Cidara Therapeutics with a rating of Buy and set a new price target of $6.00
Aegis Capital reiterated coverage of Cidara Therapeutics with a rating of Buy and set a new price target of $8.00 from $9.00 previously
WBB Securities upgraded Cidara Therapeutics from Buy to Strong Buy and set a new price target of $6.25
WBB Securities upgraded Cidara Therapeutics from Buy to Strong Buy
Aegis initiated coverage of Cidara Therapeutics with a rating of Buy and set a new price target of $9.00
Aegis initiated coverage of Cidara Therapeutics with a rating of Buy
Aegis Capital initiated coverage of Cidara Therapeutics with a rating of Buy and set a new price target of $9.00